Second Pathology Opinion for Early Breast Cancer
Posted by medconsumers on August 1, 2003
Why You Should Consider a Second Pathology Opinion for Ductal Carcinoma in Situ
By Maryann Napoli
Ductal carcinoma in situ now represents one out of every five new cases of mammography-detected breast cancer diagnosed in the U.S. Despite its ominous name, which means cancer within the milk duct of the breast, DCIS is not always destined to become deadly. Only an estimated one-third of all cases will progress to invasive breast cancer, even if left untreated. The massive rise in DCIS is due to the increased acceptance of mammography screening. But the ability to diagnose DCIS has outpaced the knowledge of how to treat it without causing too much harm. A new study conducted in the UK, New Zealand, and Australia provides some partial answers (The Lancet, 7/12/03).
No cancer agency keeps track of how DCIS is treated in the U.S, but uncertainty is clearly reflected in the range of possibilities. This microscopic lesion can be treated with excision plus six weeks of radiation therapy, breast removal, or excision alone. There is also a great deal of uncertainty about the use of the anti-breast cancer hormonal drug tamoxifen following the initial treatment.
The new study conducted by the UK Coordinating Committee on Cancer Research set out to determine which treatment or treatment combination results in a lower rate of recurrence. All of the 1,694 participants had an excisional biopsy and were then given either no further treatment, radiation therapy, or tamoxifen, or both. The recurrence rate was lower in the women given radiation therapy, as compared to women treated with surgical excision alone. But the difference between the two groups was small:TInvasive breast cancer occurred in the affected breast of 2.5% of the women given radiation therapy, compared with 5.3% in the excision alone group.
The median follow-up for this study was only four years–too short a time to know whether radiation therapy actually extends life, or if the adverse effects of radiation itself outweigh the reduced chance of recurrence. (Earlier research showed a slight increase in cardiovascular deaths among younger women given radiation therapy.) This study will have the unfortunate effect of reinforcing the current “treat all to decrease recurrences in a tiny minority” approach to radiation. As for tamoxifen, the new study found little evidence to support its use.
Two of the country’s leading breast pathologists have long been working on ways to distinguish which forms of DCIS will become invasive and which will remain dormant. Consider a second pathology opinion from Michael Lagios, MD, San Francisco (415)789-0965 (www.breastcancerconsultdr.com), or David Page, MD, Vanderbilt University, Tennessee (615)343-0072 (www.breastconsults.com).
Both will deal directly with breast cancer patients.